Farhan R, Alqarni NS, Algiraigri AH. Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma.
J Taibah Univ Med Sci 2020;
15:554-556. [PMID:
33318747 PMCID:
PMC7715481 DOI:
10.1016/j.jtumed.2020.08.004]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 08/05/2020] [Accepted: 08/23/2020] [Indexed: 11/25/2022] Open
Abstract
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare but distinct subtype of Hodgkin's lymphoma (HL) that carries a better prognosis than classical Hodgkin's lymphoma. Historically, both subtypes of Hodgkin's lymphomas (classical HL and NLPHL) have been grouped together and treated as classical Hodgkin's lymphoma. Recent studies have questioned this approach and have called for an alternative method due to expected severe long-term adverse events. We report two cases of NLPHL that were successfully treated with reduced chemotherapy cycles, as well as rituximab, in the form of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone).
Collapse